NCT00446368已完成2 期
Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- To collect data on time to tumor progression produced by the study treatment.
研究概览
简要总结
Patients with metastatic renal cell cancer will be enrolled to receive RAD001 to determine whether the use of RAD001 will result in an improvement in the time to tumor progression.
详细描述
Patients with metastatic renal cell cancer will be enrolled in the study if all eligibility criteria are met and they agree to participate. The participant will take RAD001 (Everolimus) 10mg by mouth once a day. During the first cycle, they will have blood work done once a week (4 weeks). On cycles thereafter they will have blood work on days 7 and 21. Once a month, the patient will have a chest x-ray. Every 8 weeks the patient will have a CT scan of the chest, abdomen and pelvis. If clinically indicated, additional tests will be done.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have predominantly clear cell renal cancer (75%)
- •Patients must have evidence of metastatic disease. Metastatic disease should not be progressing so as to require palliative treatment (e.g., radiation, surgery, etc), within 4 weeks of enrollment.
- •Patients may have received no more than two prior regimens such as immunotherapy, chemotherapy or molecular targeted agents for renal cell carcinoma with at least 1 regimen consisting of a tyrosine kinase inhibitor (sorafenib or sunitinib). Four weeks must have elapsed from previous therapy.
- •Patients must have adequate physiologic reserves as evidenced by lab values
- •Effective birth control must be practiced by both male and female patients
排除标准
- •Patients with central nervous system metastases are excluded, except those patients who have had complete excision or radiotherapy and remain asymptomatic, off steroids for 21 days, with no evidence of new disease as shown by MRI
- •Patients known to be HIV positive are not eligible, although testing specifically for participation in this protocol is not required.
- •Patients with a recent history of TIA (within 6 months), or are requiring regular antianginal therapy or are having claudication sufficient to limit activity are not eligible. Patients with a previous history of deep venous thrombosis or pulmonary embolism are not eligible.
- •Patients with active autoimmune disease.
- •Patients who have had steroid therapy within the past three weeks.
- •Patients involving concurrent anticancer drug therapy. Any immunosuppressive drugs or any other experimental therapy.
- •Female patients who are pregnant or lactating.
- •The patient has an unstable medical condition, such as uncontrolled diabetes mellitus or hypertension; active infections requiring systemic antibiotics, antivirals, or antifungals; clinical evidence of cardiac or pulmonary dysfunction including, but not limited to: unstable CHF; uncontrolled arrhythmias; unstable coagulation disorders; or recent myocardial infarction (within 6 months).
- •The patient has received any investigational agent(s) within 4 weeks of study entry.
- •Patients with evidence of mucosal or internal bleeding and/or platelet refractory (i.e., unable to maintain a platelet count > 50,000 cells/mm3).
- •Patients unable to maintain an absolute neutrophil count (ANC) of < 1,500 cells/mm
- •Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the patient at unacceptable risk if he/she were to participate in the study.
- •Prior malignancy (within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 3 years.
研究组 & 干预措施
RAD001
Experimental
Subjects will take RAD001 (Everolimus) 10mg by mouth daily.
干预措施: RAD001 (Drug)
结局指标
主要结局
To collect data on time to tumor progression produced by the study treatment.
时间窗: restaging every 8 weeks
次要结局
- Safety and toxicity(AEs as occur)
- Response rate(restaging every 8 weeks)
- Duration of tumor response(restaging every 8 weeks)
- Six month and 12 month survival rate(at 6 months and at 12 months)
- Overall survival(restaging every 8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)Renal Cell CarcinomaNCT00830895Seoul National University Hospital49
终止
2 期
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)Glioblastoma MultiformeNCT00515086Novartis Pharmaceuticals41
已完成
2 期
Everolimus in Treating Patients With Recurrent Low-Grade GliomaAdult Diffuse AstrocytomaAdult Mixed GliomaAdult OligodendrogliomaAdult Subependymal Giant Cell AstrocytomaRecurrent Adult Brain NeoplasmNCT00823459Susan Chang58
已完成
2 期
Everolimus as Second-line Therapy in Metastatic Renal Cell CarcinomaMetastatic Renal Cell CarcinomaNCT01491672Novartis Pharmaceuticals134
已完成
2 期
RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line TreatmentStomach NeoplasmNCT00729482Asan Medical Center54